The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer
Open accessAbstract
CONTEXT: Patients with early stage but medically inoperable lung cancer have a poor rate of primary tumor control (30%-40%) and a high rate of mortality (3-year survival, 20%-35%) with current management. OBJECTIVE: To evaluate the toxicity and efficacy of stereotactic body radiation therapy in a high-risk population of patients with early stage but medically inoperable lung cancer. DESIGN, SETTING, AND PATIENTS: Phase 2 North American multicenter study of patients aged 18 years or older with biopsy-proven peripheral T1-T2N0M0 non-small cell tumors (measuring <5 cm in diameter) and medical conditions precluding surgical treatment. The prescription dose was 18 Gy per fraction x 3 fractions (54 Gy total) with entire treatment lasting between 1(1/2) and 2 weeks. The study opened May 26, 2004, and closed October 13, 2006; data were analyzed through August 31, 2009. MAIN OUTCOME MEASURES: The primary end point was 2-year actuarial primary tumor control; secondary end points were disease-free survival (ie, primary tumor, involved lobe, regional, and disseminated recurrence), treatment-related toxicity, and overall survival. RESULTS: A total of 59 patients accrued, of which 55 were evaluable (44 patients with T1 tumors and 11 patients with T2 tumors) with a median follow-up of 34.4 months (range, 4.8-49.9 months). Only 1 patient had a primary tumor failure; the estimated 3-year primary tumor control rate was 97.6% (95% confidence interval [CI], 84.3%-99.7%). Three patients had recurrence within the involved lobe; the 3-year primary tumor and involved lobe (local) control rate was 90.6% (95% CI, 76.0%-96.5%). Two patients experienced regional failure; the local-regional control rate was 87.2% (95% CI, 71.0%-94.7%). Eleven patients experienced disseminated recurrence; the 3-year rate of disseminated failure was 22.1% (95% CI, 12.3%-37.8%). The rates for disease-free survival and overall survival at 3 years were 48.3% (95% CI, 34.4%-60.8%) and 55.8% (95% CI, 41.6%-67.9%), respectively. The median overall survival was 48.1 months (95% CI, 29.6 months to not reached). Protocol-specified treatment-related grade 3 adverse events were reported in 7 patients (12.7%; 95% CI, 9.6%-15.8%); grade 4 adverse events were reported in 2 patients (3.6%; 95% CI, 2.7%-4.5%). No grade 5 adverse events were reported. CONCLUSION: Patients with inoperable non-small cell lung cancer who received stereotactic body radiation therapy had a survival rate of 55.8% at 3 years, high rates of local tumor control, and moderate treatment-related morbidity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
TROTTI, A., COLEVAS, A., SETSER, A., RUSCH, V, JAQUES, D., BUDACH, V, LANGER, C., MURPHY, B., CUMBERLIN, R., & COLEMAN, C. (2003) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(03)00031-6 · Cited by 2,569
Timmerman, R., McGarry, R., Yiannoutsos, C., Papiez, L., Tudor, K., DeLuca, J., Ewing, M., Abdulrahman, R., DesRosiers, C., Williams, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.5937 · Cited by 1,556
Self-citationOne-Sample Multiple Testing Procedure for Phase II Clinical Trials
Fleming, T. R. (1982) · Biometrics · doi:10.2307/2530297 · Cited by 1,003
Fakiris, A. J., McGarry, R. C., Yiannoutsos, C. T., Papiez, L., Williams, M., Henderson, M. A., & Timmerman, R. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.11.042 · Cited by 838
Self-citationNagata, Y., Takayama, K., Matsuo, Y., Norihisa, Y., Mizowaki, T., Sakamoto, T., Sakamoto, M., Mitsumori, M., Shibuya, K., Araki, N., et al. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.05.034 · Cited by 672
Potters, L., Kavanagh, B., Galvin, J. M., Hevezi, J. M., Janjan, N. A., Larson, D. A., Mehta, M. P., Ryu, S., Steinberg, M., Timmerman, R., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.09.042 · Cited by 664
Self-citationLagerwaard, F. J., Haasbeek, C. J. A., Smit, E. F., Slotman, B. J., & Senan, S. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.10.053 · Cited by 534
Stereotactic Body Radiation Therapy in Multiple Organ Sites
Timmerman, R. D., Kavanagh, B. D., Cho, L. C., Papiez, L., & Xing, L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7469 · Cited by 438
Self-citation
Cited by
Lung cancer: current therapies and new targeted treatments
Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y.-L., & Paz-Ares, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30958-8 · Cited by 3,283
Non-small cell lung cancer: current treatment and future advances
Zappa, C., & Mousa, S. A. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.06.07 · Cited by 1,944
Chang, J. Y., Senan, S., Paul, M. A., Mehran, R. J., Louie, A. V., Balter, P., Groen, H. J. M., McRae, S. E., Widder, J., Feng, L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70168-3 · Cited by 1,462
Treatment of Stage I and II Non-small Cell Lung Cancer
Howington, J. A., Blum, M. G., Chang, A. C., Balekian, A. A., & Murthy, S. C. (2013) · Chest · doi:10.1378/chest.12-2359 · Cited by 1,440
Iyengar, P., Wardak, Z., Gerber, D. E., Tumati, V., Ahn, C., Hughes, R. S., Dowell, J. E., Cheedella, N., Nedzi, L., Westover, K. D., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3501 · Cited by 1,047
Self-citationCallister, M. E. J., Baldwin, D. R., Akram, A. R., Barnard, S., Cane, P., Draffan, J., Franks, K., Gleeson, F., Graham, R., Malhotra, P., et al. (2015) · Thorax · doi:10.1136/thoraxjnl-2015-207168 · Cited by 958
_, _. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0021 · Cited by 735
Delivering affordable cancer care in high-income countries
Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70141-3 · Cited by 718
Lu, K., He, C., Guo, N., Chan, C., Ni, K., Lan, G., Tang, H., Pelizzari, C., Fu, Y.-X., Spiotto, M. T., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0203-4 · Cited by 596
Annual report to the nation on the status of cancer, part 1: National cancer statistics
Cronin, K. A., Scott, S., Firth, A. U., Sung, H., Henley, S. J., Sherman, R. L., Siegel, R. L., Anderson, R. N., Kohler, B. A., Benard, V. B., et al. (2022) · Cancer · doi:10.1002/cncr.34479 · Cited by 557
Image-guided radiotherapy: from current concept to future perspectives
Jaffray, D. A. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.194 · Cited by 496
Palma, D., Visser, O., Lagerwaard, F. J., Belderbos, J., Slotman, B. J., & Senan, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.0731 · Cited by 479
Lung cancer: New biological insights and recent therapeutic advances
Ramalingam, S. S., Owonikoko, T. K., & Khuri, F. R. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20102 · Cited by 471
Videtic, G. M. M., Donington, J., Giuliani, M., Heinzerling, J., Karas, T. Z., Kelsey, C. R., Lally, B. E., Latzka, K., Lo, S. S., Moghanaki, D., et al. (2017) · Practical Radiation Oncology · doi:10.1016/j.prro.2017.04.014 · Cited by 471
Self-citationThe Magnetic Resonance Imaging–Linac System
Lagendijk, J. J. W., Raaymakers, B. W., & van Vulpen, M. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.02.009 · Cited by 464
Recent advances in the management of lung cancer
Jones, G. S., & Baldwin, D. R. (2018) · Clinical Medicine · doi:10.7861/clinmedicine.18-2-s41 · Cited by 463
Nagata, Y., Hiraoka, M., Shibata, T., Onishi, H., Kokubo, M., Karasawa, K., Shioyama, Y., Onimaru, R., Kozuka, T., Kunieda, E., et al. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.07.2278 · Cited by 449
Senthi, S., Lagerwaard, F. J., Haasbeek, C. J., Slotman, B. J., & Senan, S. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70242-5 · Cited by 447
Videtic, G. M. M., Hu, C., Singh, A. K., Chang, J. Y., Parker, W., Olivier, K. R., Schild, S. E., Komaki, R., Urbanic, J. J., & Choy, H. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.07.2260 · Cited by 414
Understanding of ROS-Inducing Strategy in Anticancer Therapy
Kim, S. J., Kim, H. S., & Seo, Y. R. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/5381692 · Cited by 406
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
Bernstein, M. B., Krishnan, S., Hodge, J. W., & Chang, J. Y. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.30 · Cited by 399
PD-1 Restrains Radiotherapy-Induced Abscopal Effect
Park, S. S., Dong, H., Liu, X., Harrington, S. M., Krco, C. J., Grams, M. P., Mansfield, A. S., Furutani, K. M., Olivier, K. R., & Kwon, E. D. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0138 · Cited by 389
Contemporary radiotherapy: present and future
Chandra, R. A., Keane, F. K., Voncken, F. E. M., & Thomas, C. R. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00233-6 · Cited by 380
Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer
Chaft, J. E., Rimner, A., Weder, W., Azzoli, C. G., Kris, M. G., & Cascone, T. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00501-4 · Cited by 375
Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment
Alduais, Y., Zhang, H., Fan, F., Chen, J., & Chen, B. (2023) · Medicine · doi:10.1097/md.0000000000032899 · Cited by 347
Lagerwaard, F. J., Verstegen, N. E., Haasbeek, C. J. A., Slotman, B. J., Paul, M. A., Smit, E. F., & Senan, S. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.06.2003 · Cited by 337
Kang, J., Kim, M., Cho, C. K., Yang, K. M., Yoo, H. J., Kim, J. H., Bae, S. H., Jung, D. H., Kim, Lee, D. H., et al. (2012) · Cancer · doi:10.1002/cncr.27533 · Cited by 334
Salama, J. K., Hasselle, M. D., Chmura, S. J., Malik, R., Mehta, N., Yenice, K. M., Villaflor, V. M., Stadler, W. M., Hoffman, P. C., Cohen, E. E. W., et al. (2012) · Cancer · doi:10.1002/cncr.26611 · Cited by 320
A Story of Hypofractionation and the Table on the Wall
Timmerman, R. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.09.027 · Cited by 308
Self-citationStereotactic body radiotherapy for colorectal liver metastases: A pooled analysis
Chang, D. T., Swaminath, A., Kozak, M., Weintraub, J., Koong, A. C., Kim, J., Dinniwell, R., Brierley, J., Kavanagh, B. D., Dawson, L. A., et al. (2011) · Cancer · doi:10.1002/cncr.25997 · Cited by 302
Videtic, G. M., Paulus, R., Singh, A. K., Chang, J. Y., Parker, W., Olivier, K. R., Timmerman, R. D., Komaki, R. R., Urbanic, J. J., Stephans, K. L., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.11.051 · Cited by 294
Self-citationScientific Advances in Lung Cancer 2015
Tsao, A. S., Scagliotti, G. V., Bunn, P. A., Carbone, D. P., Warren, G. W., Bai, C., de Koning, H. J., Yousaf-Khan, A. U., McWilliams, A., Tsao, M. S., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.03.012 · Cited by 284
“Multiple retrospective and phase I–II trials of stereotactic body radiation therapy (SBRT) have demonstrated excellent local control in early stage lung cancer.(131) To further test its efficacy, three phase III randomized trials were initiated to”
BackgroundIyengar, P., Kavanagh, B. D., Wardak, Z., Smith, I., Ahn, C., Gerber, D. E., Dowell, J., Hughes, R., Abdulrahman, R., Camidge, D. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.7412 · Cited by 286
Self-citationAshworth, A., Rodrigues, G., Boldt, G., & Palma, D. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.026 · Cited by 282
The Integration of Radiotherapy with Immunotherapy for the Treatment of Non–Small Cell Lung Cancer
Ko, E. C., Raben, D., & Formenti, S. C. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3620 · Cited by 278
High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic (HyTEC): an overview
Grimm, J., Marks, L. B., Jackson, A., Kavanagh, B. D., Xue, J., & Yorke, E. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.10.039 · Cited by 153
Chang, J. Y., Liu, Y., Zhu, Z., Welsh, J. W., Gomez, D. R., Komaki, R., Roth, J. A., & Swisher, S. G. (2013) · Cancer · doi:10.1002/cncr.28217 · Cited by 91
“Diagnosis interval (range), mo 1 (0-6) 33 (7-210)”
ResultInterruptions of head and neck radiotherapy across insured and indigent patient populations
Thomas, K., Martin, T., Gao, A., Ahn, C., Wilhelm, H., & Schwartz, D. L. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2016.017863 · Cited by 70
Sishc, B. J., Ding, L., Nam, T.-K., Heer, C. D., Rodman, S. N., Schoenfeld, J. D., Fath, M. A., Saha, D., Pulliam, C. F., Langen, B., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb3768 · Cited by 51
Metadata
- Authors
- Timmerman, R.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2010-03-17
- Volume
- 303
- Issue
- 11
- Pages
- 1070
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2115646671
- Cited by
- 2,532
- References
- 12
- FWCI
- 115.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.